SPSB1, a novel negative regulator of the transforming growth factor-β signaling pathway targeting the type II receptor

Journal of Biological Chemistry

Volumn 290, Issue 29, 2015, Pages 17894-17908

  Liu, Sheng ^a,b   Nheu, Thao ^a   Luwor, Rodney ^a   Nicholson, Sandra E ^a,b   Zh, Hong Jian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

NEGATIVE REGULATORS; PROTEIN LEVEL; SIGNALING CASCADES; SIGNALING PATHWAYS; TRANSFORMING GROWTH FACTORS; TYPE II;

SIGNALING;

CELL PROTEIN; SPSB1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; SSB-1 PROTEIN, HUMAN; SSB-1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL CELL; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; 3T3 CELL LINE; ANIMAL; CELL LINE; CELL MOTION; GENE SILENCING; GENETICS; HEK293 CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; GENE SILENCING; HEK293 CELLS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASMS; NIH 3T3 CELLS; PROTEIN INTERACTION MAPS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA; UBIQUITINATION;

EID: 84937485159     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.607184     Document Type: Article

References (84)

1. Zhu, H. J., and Burgess, A. W. (2001) Regulation of transforming growth factor-β signaling. Mol. Cell Biol. Res. Commun. 4, 321-330.
2. Inoue, Y., and Imamura, T. (2008) Regulation of TGF-β family signaling by E3 ubiquitin ligases. Cancer Sci. 99, 2107-2112.
3. Bierie, B., and Moses, H. L. (2009) Gain or loss of TGF-β signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8, 3319-3327.
4. Moustakas, A., and Heldin, C. H. (2009) The regulation of TGF-βsignal transduction. Development 136, 3699-3714.
5. Kamato, D., Burch, M. L., Piva, T. J., Rezaei, H. B., Rostam, M. A., Xu, S., Zheng, W., Little, P. J., and Osman, N. (2013) Transforming growth factor- βsignalling: role and consequences of Smad linker region phosphorylation. Cell. Signal. 25, 2017-2024.
6. Boivin, G. P., Molina, J. R., Ormsby, I., Stemmermann, G., and Doetschman, T. (1996) Gastric lesions in transforming growth factor β-1 heterozygous mice. Lab. Invest. 74, 513-518.
7. Xu, X., Brodie, S. G., Yang, X., Im, Y. H., Parks, W. T., Chen, L., Zhou, Y. X., Weinstein, M., Kim, S. J., and Deng, C. X. (2000) Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19, 1868-1874.
8. Böttinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K., and Wakefield, L. M. (1997) Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor- receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]-anthracene. Cancer Res. 57, 5564-5570.
9. Kuang, C., Xiao, Y., Liu, X., Stringfield, T. M., Zhang, S., Wang, Z., and Chen, Y. (2006) In vivo disruption of TGF-β signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc. Natl. Acad. Sci. U.S.A. 103, 1858-1863.
10. Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., Baumann, H., Judd, L. M., Giraud, A. S., Boussioutas, A., Zhu, H. J., and Ernst, M. (2005) Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat. Med. 11, 845-852.
11. Stenvers, K. L., Tursky, M. L., Harder, K. W., Kountouri, N., Amatayakul- Chantler, S., Grail, D., Small, C., Weinberg, R. A., Sizeland, A. M., and Zhu, H. J. (2003) Heart and liver defects and reduced transforming growth factor -2 sensitivity in transforming growth factor β type III receptordeficient embryos. Mol. Cell. Biol. 23, 4371-4385.
12. Massagué, J., and Chen, Y. G. (2000) Controlling TGF-β signaling. Genes Dev. 14, 627-644.
13. Wrana, J. L. (2000) Regulation of Smad activity. Cell 100, 189-192.
14. Miyazono, K., Hellman, U., Wernstedt, C., and Heldin, C. H. (1988) Latent high molecular weight complex of transforming growth factor β 1. Purification from human platelets and structural characterization. J. Biol. Chem. 263, 6407-6415.
15. Wakefield, L. M., Smith, D. M., Broz, S., Jackson, M., Levinson, A. D., and Sporn, M. B. (1989) Recombinant TGF- β 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF- β1 complex. Growth Factors 1, 203-218.
16. Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. (1990) Negative regulationof transforming growth factor- β by the proteoglycan decorin. Nature 346, 281-284.
17. Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., and Ruoslahti, E. (1992) Natural inhibitor of transforming growth factor- β protects against scarring in experimental kidney disease. Nature 360, 361-364.
18. Onichtchouk, D., Chen, Y. G., Dosch, R., Gawantka, V., Delius, H., Massague, J., and Niehrs, C. (1999) Silencing of TGF- β signalling by the pseudoreceptor BAMBI. Nature 401, 480-485.
19. Su, Y., Zhang, L., Gao, X., Meng, F., Wen, J., Zhou, H., Meng, A., and Chen, Y. G. (2007) The evolutionally conserved activity of Dapper2 in antagonizing TGF- β signaling. FASEB J. 21, 682-690.
20. Huse, M., Chen, Y. G., Massagué, J., and Kuriyan, J. (1999) Crystal structure of the cytoplasmic domain of the type I TGF β receptor in complex with FKBP12. Cell 96, 425-436.
21. Watanabe, Y., Itoh, S., Goto, T., Ohnishi, E., Inamitsu, M., Itoh, F., Satoh, K., Wiercinska, E., Yang, W., Shi, L., Tanaka, A., Nakano, N., Mommaas, A. M., Shibuya, H., Ten Dijke, P., and Kato, M. (2010) TMEPAI, a transmembrane TGF- β -inducible protein, sequesters Smad proteins from active participation in TGF- β signaling. Mol. Cell 37, 123-134.
22. Zhu, H., Kavsak, P., Abdollah, S., Wrana, J. L., and Thomsen, G. H. (1999) A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400, 687-693.
23. Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., and Miyazono, K. (2001) Smurf1 interacts with transforming growth factor- β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477-12480.
24. Nakao, A., Afrakhte, M., Morén, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N. E., Heldin, C. H., and ten Dijke, P. (1997) Identification of Smad7, a TGF β -inducible antagonist of TGF- β signalling. Nature 389, 631-635.
25. Liu, W., Rui, H., Wang, J., Lin, S., He, Y., Chen, M., Li, Q., Ye, Z., Zhang, S., Chan, S. C., Chen, Y. G., Han, J., and Lin, S. C. (2006) Axin is a scaffold protein in TGF- β signaling that promotes degradation of Smad7 by Arkadia. EMBO J. 25, 1646-1658.
26. Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., Starr, R., Nicholson, S. E., Metcalf, D., and Nicola, N. A. (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U.S.A. 95, 114-119.
27. Wang, D., Li, Z., Messing, E. M., and Wu, G. (2005) The SPRY domaincontaining SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. J. Biol. Chem. 280, 16393-16401.
28. Masters, S. L., Yao, S., Willson, T. A., Zhang, J. G., Palmer, K. R., Smith, B. J., Babon, J. J., Nicola, N. A., Norton, R. S., and Nicholson, S. E. (2006) The SPRY domain of SSB-2 adopts a novel fold that presents conserved Par-4-binding residues. Nat. Struct. Mol. Biol. 13, 77-84.
29. Ponting, C., Schultz, J., and Bork, P. (1997) SPRY domains in ryanodine receptors (Ca2+-release channels). Trends Biochem. Sci. 22, 193-194.
30. Rhodes, D. A., de Bono, B., and Trowsdale, J. (2005) Relationship between SPRY and B30.2 protein domains: evolution of a component of immune defence? Immunology 116, 411-417.
31. Kleiber, M. L., and Singh, S. M. (2009) Divergence of the vertebrate sp1A/ryanodine receptor domain and SOCS box-containing (Spsb) gene family and its expression and regulation within the mouse brain. Genomics 93, 358-366.
32. Wang, D., Li, Z., Messing, E. M., and Wu, G. (2002) Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J. Biol. Chem. 277, 36216-36222.
33. Wang, D., Li, Z., Schoen, S. R., Messing, E. M., and Wu, G. (2004) A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling. Biochem. Biophys. Res. Commun. 313, 320-326.
34. Gack, M. U., Shin, Y. C., Joo, C. H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., and Jung, J. U. (2007) TRIM25 RINGfinger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916-920.
35. Kile, B. T., Schulman, B. A., Alexander, W. S., Nicola, N. A., Martin, H. M., and Hilton, D. J. (2002) The SOCS box: A tale of destruction and degradation. Trends Biochem. Sci. 27, 235-241.
36. Masters, S. L., Palmer, K. R., Stevenson, W. S., Metcalf, D., Viney, E. M., Sprigg, N. S., Alexander, W. S., Nicola, N. A., and Nicholson, S. E. (2005) Genetic deletion of murine SPRY domain-containing SOCS box protein 2 (SSB-2) results in very mild thrombocytopenia. Mol. Cell. Biol. 25, 5639-5647.
37. Kuang, Z., Lewis, R. S., Curtis, J. M., Zhan, Y., Saunders, B. M., Babon, J. J., Kolesnik, T. B., Low, A., Masters, S. L., Willson, T. A., Kedzierski, L., Yao, S., Handman, E., Norton, R. S., and Nicholson, S. E. (2010) The SPRY domain-containing SOCS box protein SPSB2 targets iNOS for proteasomal degradation. J. Cell Biol. 190, 129-141.
38. Lewis, R. S., Kolesnik, T. B., Kuang, Z., D'Cruz, A. A., Blewitt, M. E., Masters, S. L., Low, A., Willson, T., Norton, R. S., and Nicholson, S. E. (2011) TLR regulation of SPSB1 controls inducible nitric oxide synthase induction. J. Immunol. 187, 3798-3805.
39. Nishiya, T., Matsumoto, K., Maekawa, S., Kajita, E., Horinouchi, T., Fujimuro, M., Ogasawara, K., Uehara, T., and Miwa, S. (2011) Regulation of inducible nitric-oxide synthase by the SPRY domain- And SOCS boxcontaining proteins. J. Biol. Chem. 286, 9009-9019.
40. Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C. H., and Moustakas, A. (2005) TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 16, 1987-2002.
41. Zhu, H. J., and Sizeland, A. M. (1999)Apivotal role for the transmembrane domain in transforming growth factor-beta receptor activation. J. Biol. Chem. 274, 11773-11781.
42. Kuang, Z., Yao, S., Xu, Y., Lewis, R. S., Low, A., Masters, S. L., Willson, T. A., Kolesnik, T. B., Nicholson, S. E., Garrett, T. J., and Norton, R. S. (2009) SPRY domain-containing SOCS box protein 2: crystal structure and residues critical for protein binding. J. Mol. Biol. 386, 662-674.
43. Huang, H. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X. D., Huang, C. M., Gill, G. N., Wiley, H. S., and Cavenee, W. K. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935.
44. Luwor, R. B., Johns, T. G., Murone, C., Huang, H. J., Cavenee, W. K., Ritter, G., Old, L. J., Burgess, A. W., and Scott, A. M. (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. 61, 5355-5361.
45. Luwor, R. B., Zhu, H. J., Walker, F., Vitali, A. A., Perera, R. M., Burgess, A. W., Scott, A. M., and Johns, T. G. (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23, 6095-6104.
46. Wild, R., Fager, K., Flefleh, C., Kan, D., Inigo, I., Castaneda, S., Luo, F. R., Camuso, A., McGlinchey, K., and Rose, W. C. (2006) Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther. 5, 104-113.
47. Zhu, H. J., Iaria, J., Orchard, S., Walker, F., and Burgess, A. W. (2003) Epidermal growth factor receptor: Association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand. Growth Factors 21, 15-30.
48. Zhu, H. J., Iaria, J., and Sizeland, A. M. (1999) Smad7 differentially regulates transforming growth factor β-mediated signaling pathways. J. Biol. Chem. 274, 32258-32264.
49. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J. M. (1998) Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091-3100.
50. Luwor, R. B., Wang, B., Nheu, T. V., Iaria, J., Tsantikos, E., Hibbs, M. L., Sieber, O. M., and Zhu, H. J. (2011) New reagents for improved in vitro and in vivo examination of TGF-β signalling. Growth Factors 29, 211-218.
51. Stroschein, S. L., Wang, W., Zhou, S., Zhou, Q., and Luo, K. (1999) Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science 286, 771-774.
52. Zhang, J. G., Metcalf, D., Rakar, S., Asimakis, M., Greenhalgh, C. J., Willson, T. A., Starr, R., Nicholson, S. E., Carter, W., Alexander, W. S., Hilton, D. J., and Nicola, N. A. (2001) The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. U. S. A. 98, 13261-13265.
53. Larsen, L., and Röpke, C. (2002) Suppressors of cytokine signalling: SOCS. APMIS 110, 833-844.
54. Greenhalgh, C. J., Rico-Bautista, E., Lorentzon, M., Thaus, A. L., Morgan, P. O., Willson, T. A., Zervoudakis, P., Metcalf, D., Street, I., Nicola, N. A., Nash, A. D., Fabri, L. J., Norstedt, G., Ohlsson, C., Flores-Morales, A., Alexander, W. S., and Hilton, D. J. (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J. Clin. Invest. 115, 397-406.
55. Nicholson, S. E., Metcalf, D., Sprigg, N. S., Columbus, R., Walker, F., Silva, A., Cary, D., Willson, T. A., Zhang, J. G., Hilton, D. J., Alexander, W. S., and Nicola, N. A. (2005) Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc. Natl. Acad. Sci. U.S.A. 102, 2328-2333.
56. Boyle, K., Egan, P., Rakar, S., Willson, T. A., Wicks, I. P., Metcalf, D., Hilton, D. J., Nicola, N. A., Alexander, W. S., Roberts, A. W., and Robb, L. (2007) The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 110, 1466-1474.
57. Woo, J. S., Suh, H. Y., Park, S. Y., and Oh, B. H. (2006) Structural basis for protein recognition by B30.2/SPRY domains. Mol. Cell 24, 967-976.
58. Filippakopoulos, P., Low, A., Sharpe, T. D., Uppenberg, J., Yao, S., Kuang, Z., Savitsky, P., Lewis, R. S., Nicholson, S. E., Norton, R. S., and Bullock, A. N. (2010) Structural basis for Par-4 recognition by the SPRY domainand SOCS box-containing proteins SPSB1, SPSB2, and SPSB4. J. Mol. Biol. 401, 389-402.
59. Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., Kitamura, T., Kato, H., Nakayama, K., and Yoshimura, A. (2001) The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276, 12530-12538.
60. Jakowlew, S. B. (2006) Transforming growth factorβ in cancer and metastasis. Cancer Metastasis Rev. 25, 435-457.
61. Massagué, J., and Gomis, R. R. (2006) The logic of TGF β signaling. FEBS Lett. 580, 2811-2820.
62. Liu, F. (2006) Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 17, 9-17.
63. Kretzschmar, M., Doody, J., Timokhina, I., and Massagué, J. (1999) A mechanism of repression of TGF β/Smad signaling by oncogenic Ras. Genes Dev. 13, 804-816.
64. Massagué, J., Seoane, J., and Wotton, D. (2005) Smad transcription factors. Genes Dev. 19, 2783-2810.
65. Yan, X., Lin, Z., Chen, F., Zhao, X., Chen, H., Ning, Y., and Chen, Y. G. (2009) Human BAMBI cooperates with Smad7 to inhibit transforming growth factorβ signaling. J. Biol. Chem. 284, 30097-30104.
66. Sekiya, T., Oda, T., Matsuura, K., and Akiyama, T. (2004) Transcriptional regulation of the TGFβ pseudoreceptor BAMBI by TGFβ signaling. Biochem. Biophys. Res. Commun. 320, 680-684.
67. Jin, W., Kim, B. C., Tognon, C., Lee, H. J., Patel, S., Lannon, C. L., Maris, J. M., Triche, T. J., Sorensen, P. H., and Kim, S. J. (2005) The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGFβ signaling by inactivating the TGFβ type II receptor. Proc. Natl. Acad. Sci. U.S.A. 102, 16239-16244.
68. Jin, W., Yun, C., Kwak, M. K., Kim, T. A., and Kim, S. J. (2007) TrkC binds to the type II TGFβ receptor to suppress TGFβ signaling. Oncogene 26, 7684-7691.
69. Razani, B., Zhang, X. L., Bitzer, M., von Gersdorff, G., Böttinger, E. P., and Lisanti, M. P. (2001) Caveolin-1 regulates transforming growth factor (TGF)β/SMAD signaling through an interaction with the TGFβ type I receptor. J. Biol. Chem. 276, 6727-6738.
70. Ito, T., Williams, J. D., Fraser, D. J., and Phillips, A. O. (2004) Hyaluronan regulates transforming growth factorβ1 receptor compartmentalization. J. Biol. Chem. 279, 25326-25332.
71. Suzuki, C., Murakami, G., Fukuchi, M., Shimanuki, T., Shikauchi, Y., Imamura, T., and Miyazono, K. (2002) Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J. Biol. Chem. 277, 39919-39925.
72. Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H. R., Zhang, Y., and Wrana, J. L. (2005) Regulation of the polarity protein Par6 by TGFβreceptors controls epithelial cell plasticity. Science 307, 1603-1609.
73. Atfi, A., Dumont, E., Colland, F., Bonnier, D., L'Helgoualc'h, A., Prunier, C., Ferrand, N., Clément, B., Wewer, U. M., and Théret, N. (2007) The disintegrin and metalloproteinase ADAM12 contributes to TGFβ signaling through interaction with the type II receptor. J. Cell Biol. 178, 201-208.
74. Kugler, J. M., Woo, J. S., Oh, B. H., and Lasko, P. (2010) Regulation of Drosophila vasa in vivo through paralogous cullin-RING E3 ligase specificity receptors. Mol. Cell. Biol. 30, 1769-1782.
75. Centrella, M., Casinghino, S., Kim, J., Pham, T., Rosen, V., Wozney, J., and McCarthy, T. L. (1995) Independent changes in type I and type II receptors for transforming growth factor - induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype. Mol. Cell. Biol. 15, 3273-3281.
76. Centrella, M., Ji, C., Casinghino, S., and McCarthy, T. L. (1996) Rapid flux in transforming growth factorβ receptors on bone cells. J. Biol. Chem. 271, 18616-18622.
77. De Boer, W. I., Houtsmuller, A. B., Izadifar, V., Muscatelli-Groux, B., Van der Kwast, T. H., and Chopin, D. K. (1997) Expression and functions of EGF, FGF and TGF-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int. J. Cancer 71, 284-291.
78. Koli, K. M., and Arteaga, C. L. (1997) Processing of the transforming growth factor - type I and II receptors: biosynthesis and ligand-induced regulation. J. Biol. Chem. 272, 6423-6427.
79. Anders, R. A., Doré, J. J. Jr., Arline, S. L., Garamszegi, N., and Leof, E. B. (1998) Differential requirement for type I and type II transforming growth factor βreceptor kinase activity in ligand-mediated receptor endocytosis. J. Biol. Chem. 273, 23118-23125.
80. Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., and Wrana, J. L. (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF β receptor for degradation. Mol. Cell 6, 1365-1375.
81. Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., and Liu, F. (2004) Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226-231.
82. Akhurst, R. J., and Derynck, R. (2001) TGFβ signaling in cancer: A doubleedged sword. Trends Cell Biol. 11, S44-S51.
83. Rahimi, R. A., and Leof, E. B. (2007) TGFβ signaling: A tale of two responses. J. Cell. Biochem. 102, 593-608.
84. Siegel, P. M., and Massagué, J. (2003) Cytostatic and apoptotic actions of TGFβ in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821.